Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells

Nanomedicine applications in the treatment of breast cancer: current state of the art

(2017) Di Wu et al.   International Journal of Nanomedicine

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

Targeting natural killer cells in cancer immunotherapy

(2016) Camille Guillerey et al.   NATURE IMMUNOLOGY

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies

(2016) Miriam Colombo et al.   Nature Communications

Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes

(2015) Qijia Xuan et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact

(2014) Daniel Rayson et al.   Breast Journal

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

(2014) Milos Dokmanovic et al.   CANCER BIOLOGY & THERAPY

Assessing the In Vivo Targeting Efficiency of Multifunctional Nanoconstructs Bearing Antibody-Derived Ligands

(2013) Luisa Fiandra et al.   ACS Nano

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

(2013) Branka Petricevic et al.   Journal of Translational Medicine

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer

(2013) J.-K. Rhee et al.   NUCLEIC ACIDS RESEARCH

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

(2013) A. B. Hanker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biotechnological approaches toward nanoparticle biofunctionalization

(2013) Svetlana Avvakumova et al.   TRENDS IN BIOTECHNOLOGY

Dependence of nanoparticle-cell recognition efficiency on the surface orientation of scFv targeting ligands

(2013) Serena Mazzucchelli et al.   Biomaterials Science

Controlled antibody/(bio-) conjugation of inorganic nanoparticles for targeted delivery

(2012) Jose-Maria Montenegro et al.   ADVANCED DRUG DELIVERY REVIEWS

HER2 Expression in Breast Cancer Cells Is Downregulated Upon Active Targeting by Antibody-Engineered Multifunctional Nanoparticles in Mice

(2011) Fabio Corsi et al.   ACS Nano

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

(2011) D. M. Collins et al.   ANNALS OF ONCOLOGY

Multiple Presentation of Scfv800E6 on Silica Nanospheres Enhances Targeting Efficiency Toward HER-2 Receptor in Breast Cancer Cells

(2011) Serena Mazzucchelli et al.   BIOCONJUGATE CHEMISTRY

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

(2011) Devika Gajria et al.   Expert Review of Anticancer Therapy

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

(2010) Katri Köninki et al.   CANCER LETTERS

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL